CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 86 enrolled
Drug / intervention
CFAE ablationprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00926783
NCT00926783Phase 4Completed
CompareCT.gov

Selective CFAE Targeting for Atrial Fibrillation (SELECT-AF)

Biosense Webster, Inc.·interventional·Posted Jun 24, 2009·Updated Jun 10, 2014

In Brief

A Phase 4 clinical trial evaluating CFAE ablation for Atrial Fibrillation. Completed, enrolled 86 participants across 7 sites in 3 countries.

Detailed Summary

This study will be a multicenter, open, prospective, randomized trial. Patients with either paroxysmal or persistent atrial fibrillation will be considered for the study. (For US, only paroxysmal atrial fibrillation will be considered.) Eligible subjects will be randomized into one of two arms in the study: (1) targeted CFAE ablation or (2) generalized CFAE ablation. Both techniques will then be followed by PVAI (pulmonary vein antral isolation) as part of a hybrid ablation strategy. The nature of the ablation procedures does not allow physicians to be blinded to the randomization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesAustralia, Canada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 24, 2009
Enrollment StartAug 1, 2009
Primary CompletionNov 1, 2011
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.0 years ago

Interventions

CFAE ablationprocedure

CFAE ablation (targeted vs. generalized)